Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2026 | $32.00 | Buy | Canaccord Genuity |
| 1/30/2026 | $25.00 | Outperform | Mizuho |
| 7/7/2025 | $22.00 | Outperform | Oppenheimer |
| 2/10/2022 | $43.00 → $20.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $46.00 → $43.00 | Buy | HC Wainwright & Co. |
| 7/27/2021 | $28.00 | Overweight | Stephens & Co. |
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
Canaccord Genuity initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $32.00
Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00
Oppenheimer initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $22.00
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 3486060. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors websi
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).Pulse has awarded inducement options to three new employees to purchase, in aggregate, up to 9,000 shares of Company common stock. The Company’s independent Compensat
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the "200% Warrants"), which were issued in the Company's 2024 rights offering (the "Rights Offering"), pursuant to the Company's Registration Statement on Form S-3, as amended (File No. 333-278494), may be exercised by the holders thereof until 5:00 p.m., Eastern time, on July 13, 202
4/A - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4/A - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)
Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg's Chief Medical Officer Role Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the strengthening of its executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer and expanded role of Dr. David Kenigsberg as full-time Chief Medical Officer. Both the appointment of Liane Teplitsky as Chief Operating Officer and Dr. David Kenigsberg's agreement to serve as the Company's Chief Medical Officer on a full-time basis further enhance the Company's strategic alignment to priori
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m
Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 3486060. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors websi
Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonstrating exceptional procedure efficiency and durable outcomes. Pre
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv